FDA approves 2nd drug vs COVID-19 | Inquirer News
FOR MILD, MODERATE CASES

FDA approves 2nd drug vs COVID-19

/ 05:20 AM March 12, 2022

FDA okays pill for chronic kidney disease

FILE PHOTO: Facade of FDA office.

MANILA, Philippines — The Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for paxlovid, making it the second antiviral drug approved to treat mild to moderate cases of COVID-19 in the country.

FDA Deputy Director General Oscar Gutierrez, the agency’s officer in charge, said at the Laging Handa briefing that paxlovid was the latest antiCOVID drug that was granted regulatory approval.

ADVERTISEMENT

A new brand of another antiviral pill, molnupiravir, was also given an EUA last week, he said.

FEATURED STORIES

“I am happy to announce that we have already approved paxlovid yesterday and … another brand of molnupiravir from Bangladesh,” Gutierrez said on Friday.

An EUA is issued to unregistered drugs and vaccines in a public health emergency. But FDA earlier warned the public that an EUA is not a marketing authorization so the drug cannot be sold commercially.

Developed by pharmaceutical company Pfizer, paxlovid was designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure. This would help high-risk patients prevent severe infection that can lead to hospitalization and death.

In November last year, Pfizer authorized generic manufacturers to supply paxlovid to low- and middle-income countries such as the Philippines through a licensing agreement.

With the latest EUA issuance, there are now two oral antiviral drugs against COVID-19. The FDA first granted EUA for Molnarz, another brand of molnupiravir produced by an Indian manufacturer, in December last year.

RELATED STORIES

ADVERTISEMENT

FDA approves generic version of Pfizer’s COVID-19 pill Paxlovid

FDA allows use of more molnupiravir brands; Pfizer seeks nod for Paxlovid

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: COVID-19, molnupiravir, Paxlovid, Pfizer, pill, treatment

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.